
Finding Lung Cancer Before It’s Too Late: From Uncertainty to Action
Show notes
In this episode of Diagnosing Dx, I’m joined by Maria Zannes, Chief Executive Officer and Director at bioAffinity Technologies.
Maria shares her journey from journalism and business leadership into diagnostics, and explains how bioAffinity Technologies is building a non-invasive platform for lung disease diagnosis, starting with early lung cancer detection. We explore the limitations of current pathways for indeterminate pulmonary nodules, how CyPath Lung is designed to support faster, more confident decision-making, and why earlier detection can have such a major impact on outcomes.
We also discuss what it really takes to build and scale in diagnostics, from clinical validation and workflow adoption to balancing commercialization with continued innovation. From lung cancer screening and clinical trials to asthma, COPD, and future opportunities in the platform, this is a practical conversation about bringing meaningful diagnostic advances to market.
Key takeaways:
🔹 Why early detection remains one of the biggest opportunities in lung cancer care
🔹 How non-invasive testing could improve patient comfort and clinical decision-making
🔹 Why strong science, clinical validation, and commercial execution all matter in diagnostics
🔹 How bioAffinity Technologies is balancing commercialization with continued discovery and innovation
🔹 What the company’s upcoming military and VA clinical trial could mean for wider adoption
Chapters:
00:00 Introduction
02:24 Why Texas is becoming a hub for diagnostics companies
02:58 Maria Zannes’ background and the origins of bioAffinity Technologies
05:42 Personal motivation, team building, and the role of science in innovation
09:27 bioAffinity’s platform technology and how CyPath Lung works
11:31 Early lung cancer detection, screening awareness, and non-invasive testing
16:25 Commercial strategy, test performance, and real-world use cases
20:02 Team growth, company milestones, and the journey to commercialization
23:27 Clinical validation, the upcoming military and VA trial, and the economic case for CyPath Lung
31:36 Company setup, future growth, therapeutic potential, and what’s next
Guest:
Maria Zannes
LinkedIn: https://www.linkedin.com/in/maria-zannes-32496815/
Host:
David Filby
LinkedIn: https://www.linkedin.com/in/davidfilby/
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.